Dessau-Roßlau (dpa/sa) – The pharmaceutical company Merz has invested around 40 million euros in its Dessau-Roßlau site. A bottling plant and a multifunctional building were built with the money, as a spokeswoman for the investment and marketing company (IMG) Saxony-Anhalt announced on Wednesday. The expansion would also create 50 new jobs. IMG looks after the company in the country.
Merz has been manufacturing aesthetic and neurological products at Biopharmapark Dessau-Roßlau since 2002. According to the spokeswoman, the company is now aligning its production with “particularly high-revenue products”, such as Xeomin, which is used in neurological movement disorders, and Bocouture, a product for aesthetic medicine.
The family-run company has its headquarters in Frankfurt am Main and has several production sites in Germany and other countries.
